Robert B. Bazemore - Sep 17, 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact for Robert B. Bazemore
Stock symbol
AKTX
Transactions as of
Sep 17, 2024
Transactions value $
$0
Form type
4
Date filed
9/18/2024, 04:40 PM
Previous filing
Sep 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +5M $0.00 5M Sep 17, 2024 Ordinary Shares, par value $0.0001 per share 5M $0.00 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share ("Ordinary Share").
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Remarks:

Exhibit 24 - Power of Attorney